ALPINE IMMUNE SCIENCES, INC.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $58.9M | $30.1M | $23.4M | $9.3M | $1.7M | $705,000 |
| Operating income | −$44.3M | −$58.1M | −$49.9M | −$28.7M | −$43.6M | −$37.8M |
| Net income | −$32.2M | −$57.8M | −$50.3M | −$27.9M | −$41.9M | −$36.5M |
| Total assets | $379.9M | $286.7M | $255.9M | $144.1M | $54.1M | $54.9M |
| Total liabilities | $51.9M | $107.3M | $135.0M | $81.9M | $24.6M | $10.3M |
| Equity | $327.9M | $179.4M | $120.9M | $62.2M | $29.5M | $44.6M |
| EPS (diluted) | $-0.64 | $-1.73 | $-1.98 | $-1.34 | $-2.28 | — |
| Shares out. | 47.8M | 30.3M | 23.9M | 18.6M | 18.6M | 13.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −75.2%
- Net margin
- −54.7%
- Return on equity
- −9.8%
- Return on assets
- −8.5%
- Return on capital (ROCE)
- −13.1%
- Liabilities / assets
- 13.7%
- Debt / equity
- 0.16×
- Book value / share
- $6.87
- Revenue growth (YoY)
- 95.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- 8.63safe
- Accruals / assets
- 12.3%high accruals
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 4 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- High accruals — earnings-quality risk
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Active Not Recruitingreadout ~2026-07An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
- Phase 3Active Not Recruitingreadout ~2028-01-30Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
- Phase 1/2Active Not Recruitingreadout ~2028-03-02An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Peetz ChristopherDirector | May 20, 2024 | D | 1,900 | — |
| Conway Robert EDirector | May 20, 2024 | D | 50,000 | — |
| Topper James NDirector | May 18, 2024 | U | 2.8M | — |
| Thompson Peter A.Director | May 18, 2024 | U | 2.4M | — |
| Cui XiangminDirector | May 18, 2024 | U | 6.6M | — |
| Rickey James PaulOfficer — See Remarks | May 20, 2024 | D | 26,761 | — |
| Peng Stanford LOfficer — See Remarks | May 20, 2024 | D | 296,163 | — |
| Gold MitchellOfficer — Executive Chairman and CEO | May 18, 2024 | U | 2.6M | — |
| Fuhs Ulrich MartinOfficer — Chief Accounting Officer | May 20, 2024 | D | 22,820 | — |
| Durand RemyOfficer — Chief Business Officer | May 20, 2024 | D | 102,192 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMay 20, 2024
- Results of operations · Regulation FD disclosureMay 9, 2024
- Entered a material agreement · Other material eventApr 10, 2024
- Director / officer changeApr 5, 2024
- Results of operations · Regulation FD disclosureMar 18, 2024
- Unregistered equity sale · Other material eventFeb 7, 2024
- Director / officer changeJan 5, 2024
- Entered a material agreementDec 21, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.